Morrison & Foerster advised biopharmaceutical company Adicet Bio, Inc. in connection with the completion of its $80 million Series B financing, announced on October 2, 2019.
Adicet Bio focuses on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells and intends to use the financing to continue developing its proprietary technology, to enter the clinic in Non-Hodgkin's Lymphoma, and to advance its solid tumor programs.
The MoFo deal team was led out of San Diego by corporate partners Jim Krenn and Jay de Groot, and included associates Brennen Brodersen and Kevin McKenna.
Read the related press release.